Roche announces that its VENTANA MMR RxDx Panel, a companion diagnostic for precision oncology, has received approval under the EU In Vitro Diagnostic Regulation (IVDR) for use across multiple cancer types and therapies. The test is designed to act as a predictive biomarker by evaluating a panel of mismatch repair (MMR) proteins in tumour samples. According to the company, the results help identify which patients are eligible for treatment with certain precision oncology therapies. Roche states that the panel is intended to provide clinicians with a standardized testing option, using the assessment of MMR protein status to support treatment selection. The announcement comes through PR Newswire, and the reported details focus on the scope of IVDR approval and the diagnostic’s role in matching patients to therapies based on tumour biomarker evaluation. The sources do not provide additional figures on the number of cancer types, specific therapies included, or clinical performance metrics. All available information centers on regulatory approval and the intended clinical use of the companion diagnostic.